Five Notable Stock Decliners on October 6, 2026

• Five stocks recorded declines ranging from 17.5% to 50.1% on October 6.

• ArriVent BioPharma fell after its lung cancer treatment failed to meet a Phase 3 trial’s primary endpoint.

• Twist Bioscience and 10x Genomics declined amid a broader selloff in genomics and testing stocks.

Armada Acquisition Corp. II (NASDAQ: XRPN) plunged 50.1% to $19.20 amid volatility ahead of its planned business combination with Evernorth. The transaction is expected to close on October 7, with the combined company scheduled to begin trading as Evernorth under the XRPN ticker on October 8. Evernorth expects approximately $300 million in gross cash proceeds and holdings of about 473 million XRP at closing.

ArriVent BioPharma (NASDAQ: AVBP) dropped 46.9% to $15.09 after firmonertinib failed to meet the primary endpoint in a Phase 3 lung cancer trial. Approximately 19.7 million shares changed hands.

WISeSat.Space Holdings (NASDAQ: SAIQ) declined 23.7% to $5.16, reversing part of its sharp gain from the previous session. No specific company announcement was identified as the cause of the decline.

Twist Bioscience (NASDAQ: TWST) fell 18.6% to $166.97 on approximately 7.91 million shares. No clear company-specific catalyst was established, although genomics and testing stocks experienced a broader selloff.

10x Genomics (NASDAQ: TXG) lost 17.5% to $80.66, with approximately 9.04 million shares traded. The available information does not identify a specific company announcement behind the decline.